tag:blogger.com,1999:blog-36768584.post7162683415272146545..comments2024-03-03T18:49:34.382-05:00Comments on Omics! Omics!: Genia Publishes Polymerase-to-pore docking schemeKeith Robisonhttp://www.blogger.com/profile/04765318239070312590noreply@blogger.comBlogger4125tag:blogger.com,1999:blog-36768584.post-89765136058381294852016-11-01T03:19:03.404-04:002016-11-01T03:19:03.404-04:00The patent in the ILMN suit was only valid in the ...The patent in the ILMN suit was only valid in the US. Thrown out everywhere else. nowhere, including in the legal documents, can I find anything resembling an admission of infringement. As you must know, settling a case can present a better risk\reward profile than taking it all the way, isn't that at the heart of the US legal system? Perhaps, a REasonable person may also view the settlement as an admission by ILMN of ONTs counter case/defence. Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-36768584.post-54133404896930207452016-10-30T04:07:59.552-04:002016-10-30T04:07:59.552-04:00My sense is that there is nothing in ONT's pat...My sense is that there is nothing in ONT's patent portfolio that can touch Genia. If there is a problem it is with PacB and phosphate labeled nucleotides. <br /><br />As an editorial note I am suspecting that if ONT sues Roche they will be labeled as a laudable case of David taking on Goliath and the calls to let the companies duke it out in the marketplace will be few and far between. Funny how that was not the case with the mspA dispute with Illumina. And how this and practically every other blog failed to discuss the outcome of that dispute in any detail, or cover the fact that ONT seems to have essentially admitted to infringing on the patent in question with everything up to and including the R7 chemistry Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-36768584.post-18037538323399481912016-10-21T06:10:02.020-04:002016-10-21T06:10:02.020-04:00So my feeling of briefly skimming the paper was th...So my feeling of briefly skimming the paper was that it add further details, but not much in terms of development over the previous publication.<br /><br />Don't know about the IP position, it seems like a very different system to anything ONT have suggested.newhttps://www.blogger.com/profile/16659709753088495544noreply@blogger.comtag:blogger.com,1999:blog-36768584.post-39245336111532548272016-10-20T15:46:22.079-04:002016-10-20T15:46:22.079-04:00Keith, are you wiling to take a guess at how long ...Keith, are you wiling to take a guess at how long it might be to get your hands on an early access device?<br /><br />Similar approaches have been taken before, I'd say it's somewhat similar to the Illumina/ONT 'exonuclease sequencing' in the fact that something gets clipped off a DNA base and transits through the pore to create the signal. Do you have any comments on how well the covalent attachment is likely to affect kinetics/dynamics - does PacBio offer some glimpse into the types of bias this method might have?<br /><br />As with the first ONT MinION I'm sure this system can be improved, but it's unclear if Roche will give Genia that much time and money! Especially given the IP landscape...I'd like to see you write an article on that front!<br />James@cancerhttps://www.blogger.com/profile/02825715598810395734noreply@blogger.com